Pharmacological regulation of the tumor immuno environment
Journal of Pharmaceutical Care & Health Systems

Journal of Pharmaceutical Care & Health Systems
Open Access

ISSN: 2376-0419

Pharmacological regulation of the tumor immuno environment

European Pharma Congress

August 25-27, 2015 Valencia, Spain

Michael R Shurin

University of Pittsburgh Medical Center, USA

Posters-Accepted Abstracts: J Pharma Care Health Sys

Abstract :

The tumor microenvironment consist of a variable combination of tumor cells, stromal fibroblasts, endothelial cells and infiltrating leukocytes, such as macrophages, T lymphocytes, and Dendritic Cells (DC). Tumor progression is often associated with suppression or malfunction of the immune system, including the appearance of regulatory T cells and myeloid-derived suppressor cells, dysbalance of dendritic cell subsets and cytokine network, and polarization of Th1/Th2/Th3/Th17/Treg subsets and their balance. We have recently reported that antineoplastic chemotherapeutic agents could directly up-regulate development and functional activation of dendritic cells in vitro and in vivo if used in low nontoxic concentrations. Our new data revealed that low-dose nontoxic chemotherapy (or chemomodulation) increases resistance of dendritic cells to tumor-induced immunosuppression and converts suppressor dendritic cells into immunostimulatory cells. Furthermore, low-dose nontoxic chemotherapy down-regulated activity of myeloid-derived suppressor cells and regulatory T cells in the tumor microenvironment. Finally, antineoplastic chemotherapeutic agents in low, nontoxic concentrations blocked the ability of tumor cells to inhibit immune cell function. This effect was associated with increased expression of antigen-processing machinery components in tumor cells and, thus, increased immunogenicity of tumor cells. Together, these data suggest that the modulation of the tumor microenvironment by low-dose nontoxic chemotherapy ΓΆΒ?Β? chemomodulation, - may serve as a powerful adjuvant for different immunotherapeutic modalities in cancer. In fact, application of low-dose chemotherapy prior to dendritic cell vaccines in the animal tumor models resulted in significant inhibition of primary and metastatic tumor growth in vivo. Thus, chemomodulation of the tumor environment with nontoxic doses of several common chemotherapeutic agents, including nanovehicle delivery of these agents, might target different cell populations, decrease tumorinduced immunosuppression, and improve the efficacy of modern vaccines for cancer therapy.

Biography :

Email: [email protected]